Pfizer’s Geno Germano Talks M&A Strategy
The big pharma is evaluating a full spectrum of M&A opportunities, Pfizer Global Innovative Pharma Business President Germano said in an interview. Whether that includes another bid for AstraZeneca remains to be seen, but when it comes to a potential tax inversion deal, he said business is business.
You may also be interested in...
Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership
Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.
First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.
Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.